logo
Share SHARE
FONT-SIZE Plus   Neg

Enanta Enters Into Strategic Collaboration With Novartis For EDP-239

Private Equity Holding AG or PEH announced that a portfolio company Enanta Pharmaceuticals has entered into a strategic collaboration with Novartis AG (NVS) for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus or HCV inhibitor program.

PEH is a minority shareholder and invested in Enanta in 1999 as part of the original shareholder syndicate.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Abbott Laboratories (ABT) reported a profit for the second-quarter 2017 declined about 54.1 percent from last year, hurt by higher costs. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. Abbott raised its full-year 2017 earnings per share guidance range. Consumer goods giant Unilever plc reported Thursday higher profit in its first half, with increased sales and margin. Looking ahead, the company said it is on track for another year of underlying sales growth ahead of markets. German business software maker SAP AG reported Thursday a decline in second-quarter profit amid higher expenses. Revenues, however, increased from last year with growth in all regions. Further, the company lifted its forecast for fiscal 2017 revenues. The company also announced a share buyback of up to 500 million euros in the second half.
comments powered by Disqus
Follow RTT